Loading...
01/10 16:12
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings report shows strong financial performance with record revenue and net income growth, improved margins, and significant share repurchases. The Q&A session addresses potential risks like regulatory impacts and higher medical costs, but management remains optimistic about growth, particularly in digital and healthcare sectors. Despite some uncertainties, the positive guidance and strategic focus on expansion suggest a positive outlook. Given the company's small market cap, the stock is likely to react positively, with a potential increase of 2% to 8% over the next two weeks.
Revenue (RBR) Q4 2024 $388.4 million, up 14.5% from $339.2 million in Q4 2023, driven by solid growth across all three operating segments.
Revenue (RBR) Full Year 2024 $1.49 billion, up 9.1% from $1.36 billion in 2023, on top of strong growth of 20.3% in 2023 over 2022.
Net Income Q4 2024 $34 million or $1.84 per diluted share, compared to $2.8 million or $0.15 per diluted share in Q4 2023, with net income as a percentage of total revenues increasing to 8.5% from 0.8%.
Net Income Full Year 2024 $116.6 million or $6.27 per diluted share, compared to $62.5 million or $3.19 per diluted share in 2023, with net income as a percentage of total revenues increasing to 7.7% from 4.5%.
Adjusted EBITDA Q4 2024 $56.8 million or 14.6% of RBR, compared to $41.4 million or 12.2% of RBR in Q4 2023.
Adjusted EBITDA Full Year 2024 Increased to 13.5% of RBR from 12.3% in 2023, primarily due to increased segment operating income in Healthcare and Education segments.
Adjusted Net Income Q4 2024 $35.2 million or $1.90 per diluted share, compared to $25.1 million or $1.29 per diluted share in Q4 2023.
Adjusted Net Income Full Year 2024 $120.4 million or $6.47 per share, compared with $96.2 million or $4.91 per share in 2023.
Cash Flow from Operations Full Year 2024 $201 million, resulting in record free cash flow of $168 million after $33 million in capital expenditures.
Total Debt as of December 31, 2024 $357.7 million, with net debt of $335.8 million, an $89 million decrease in net debt compared to Q3 2024.
Share Repurchases Full Year 2024 $122 million used to repurchase approximately 1.2 million shares, representing 6.6% of outstanding shares at the beginning of the year.
Leverage Ratio as of December 31, 2024 1.4 times adjusted EBITDA, compared to 1.6 times adjusted EBITDA as of December 31, 2023.
New Product Acquisition: Acquisition of AXIA Consulting, a leading provider of supply chain focused consulting and technology solutions, enhancing Oracle supply chain management offerings.
Healthcare Segment Growth: Healthcare segment RBR grew 18% in Q4 2024 and 12% for the full year, achieving record RBR of $756 million.
Education Segment Growth: Education segment RBR increased 15% in Q4 2024, driven by digital and strategy offerings, achieving record RBR of $474 million.
Commercial Segment Growth: Commercial segment RBR grew 6% in Q4 2024, driven by AXIA acquisition and financial advisory offerings.
Record Cash Flow: Generated record cash flow from operations of $201 million in 2024.
Share Repurchases: Returned over $122 million to shareholders via share repurchases in 2024.
Integrated Growth Strategy: Continued execution of integrated growth strategy, focusing on healthcare and education markets while expanding commercial presence.
Divestiture of Studer Education: Completed divestiture of Studer Education business on December 31, 2024, to concentrate resources on core market focus.
Healthcare Segment Risks: Declining provider margins due to rising labor and supply costs outpacing revenue increases, necessitating further actions for financial sustainability amid a dynamic regulatory environment.
Regulatory Risks in Healthcare: Potential changes in clinical reimbursement models, federal funding levels for Medicaid, and tax exemption statuses could impact financial performance.
Supply Chain Challenges: Health systems are evaluating potential reductions in reimbursement for 340B eligible drugs and the impact of tariffs on supply costs.
Education Segment Risks: Anticipated reductions in federal research funding and indirect cost reimbursement rates could significantly impact research-intensive institutions.
Regulatory Environment in Education: Changes in immigration policies, deregulation at federal and regional accreditation levels, and taxation of endowments pose additional risks.
Commercial Segment Risks: Macroeconomic and geopolitical uncertainties are causing clients to be cautious about large-scale engagements, impacting demand for strategy and innovation offerings.
Overall Economic Factors: Ongoing market uncertainty and evolving regulatory environments are expected to continue affecting client demand across all segments.
Growth Strategy: Huron's integrated growth strategy has driven record revenues and expanded adjusted EBITDA margins for the fourth consecutive year, with a focus on healthcare and education segments.
Acquisition of AXIA: The acquisition of AXIA Consulting enhances Huron's supply chain management offerings and broadens its technology portfolio.
Divestiture of Studer Education: The divestiture of the Studer Education business allows Huron to concentrate resources on areas that align with market focus and drive higher returns.
Market Positioning: Huron aims to leverage its leading market positions in healthcare and education while expanding its presence in commercial industries.
Revenue Guidance for 2025: Huron anticipates revenues before reimbursable expenses in the range of $1.58 billion to $1.66 billion, reflecting a 9% year-over-year growth at the midpoint.
Adjusted EBITDA Margin Guidance: Expected adjusted EBITDA margin in a range of 14% to 14.5% of RBR, reflecting a 75 basis point improvement over 2024.
Adjusted EPS Guidance: Projected adjusted diluted earnings per share of $6.80 to $7.60, reflecting an 11% increase over 2024.
Cash Flow Guidance: Cash flows from operations are expected to be in a range of $195 million to $235 million.
Capex Guidance: Capital expenditures are expected to be approximately $35 million to $45 million.
Tax Rate Guidance: Effective tax rate is expected to be in the range of 28% to 30%.
Share Repurchases: In 2024, Huron Consulting Group returned over $122 million of capital to shareholders via share repurchases, which included approximately 1.2 million shares, representing 6.6% of outstanding shares at the beginning of the year.
Share Repurchases in Q4 2024: In the fourth quarter of 2024, the company repurchased $18.2 million worth of shares, approximately 151,000 shares.
The earnings call presents strong financial performance with increased revenue, net income, and adjusted EBITDA. The guidance is optimistic, with anticipated growth across segments and strategic acquisitions. The Q&A section reveals positive sentiment from analysts, highlighting strong demand and effective management strategies. Although management avoided specific guidance for 2026, the overall outlook remains positive. Given the company's market cap, a positive stock price movement of 2% to 8% is likely over the next two weeks.
The earnings call highlights strong financial performance across segments, reaffirmed guidance, and record sales conversions, which are positive indicators. The Q&A session reveals improved visibility and confidence in overcoming temporary delays, though some responses lacked specific data. The market cap suggests moderate sensitivity to news. Overall, the combination of strong results, strategic acquisitions, and positive guidance adjustments suggests a positive stock price movement, likely in the range of 2% to 8% over the next two weeks.
The earnings call revealed strong financial performance with record revenue growth and improved margins. Despite some concerns in the Q&A about strategy consulting and macroeconomic impacts, the overall sentiment remains positive due to strong guidance, a decrease in leverage ratio, and increased demand across segments. The market cap suggests a moderate reaction, leading to a prediction of a 2% to 8% stock price increase.
The earnings report shows strong financial performance with record revenue and net income growth, improved margins, and significant share repurchases. The Q&A session addresses potential risks like regulatory impacts and higher medical costs, but management remains optimistic about growth, particularly in digital and healthcare sectors. Despite some uncertainties, the positive guidance and strategic focus on expansion suggest a positive outlook. Given the company's small market cap, the stock is likely to react positively, with a potential increase of 2% to 8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
